(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 12.85% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Supernus Pharmaceuticals's revenue in 2026 is $830,438,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $51,419,736,970, with the lowest SUPN revenue forecast at $48,932,482,084, and the highest SUPN revenue forecast at $53,251,900,420. On average, 8 Wall Street analysts forecast SUPN's revenue for 2027 to be $60,452,093,520, with the lowest SUPN revenue forecast at $56,756,378,033, and the highest SUPN revenue forecast at $63,649,079,235.
In 2028, SUPN is forecast to generate $69,345,526,509 in revenue, with the lowest revenue forecast at $63,474,698,196 and the highest revenue forecast at $73,763,179,497.